Free Trial
NASDAQ:KPRX

Kiora Pharmaceuticals Q1 2024 Earnings Report

Kiora Pharmaceuticals logo
$2.78 -0.08 (-2.80%)
Closing price 03:59 PM Eastern
Extended Trading
$2.83 +0.05 (+1.80%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Kiora Pharmaceuticals EPS Results

Actual EPS
$3.42
Consensus EPS
$5.58
Beat/Miss
Missed by -$2.16
One Year Ago EPS
N/A

Kiora Pharmaceuticals Revenue Results

Actual Revenue
$16.00 million
Expected Revenue
$16.00 million
Beat/Miss
Met Expectations
YoY Revenue Growth
N/A

Kiora Pharmaceuticals Announcement Details

Quarter
Q1 2024
Time
N/A
Conference Call Date
Friday, May 10, 2024
Conference Call Time
7:00AM ET

Upcoming Earnings

Kiora Pharmaceuticals' Q3 2025 earnings is scheduled for Friday, November 14, 2025, with a conference call scheduled on Friday, November 7, 2025 at 7:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Kiora Pharmaceuticals Earnings Headlines

Kiora (KPRX) Q2 Revenue Falls 100%
Why More Investors Are Using Family Trusts to Protect Their Wealth
For many investors, a family trust can be an essential tool for protecting assets, avoiding probate, and ensuring wealth is passed on according to your wishes. Trusts may also provide shielding from creditors and lawsuits while offering potential tax advantages—especially with estate tax thresholds set to decrease in 2026. If you’re considering whether a family trust is right for you, speaking with a fiduciary financial advisor can help you decide the best path forward. We’ve created a free tool that matches you with vetted advisors in your area—each legally bound to act in your best interest.tc pixel
See More Kiora Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Kiora Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Kiora Pharmaceuticals and other key companies, straight to your email.

About Kiora Pharmaceuticals

Kiora Pharmaceuticals (NASDAQ:KPRX), a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1b clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases. The company is also developing KIO-101, an eye drop that is in Phase 2 clinical trial for the treatment of ocular presentation of rheumatoid arthritis, and KIO-104 for the treatment of posterior non-infectious uveitis; and KIO-201, an eye drop, which is in Phase 3b clinical trial for treating patients undergoing photorefractive keratectomy (PRK) surgery for corneal wound repair. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Encinitas, California.

View Kiora Pharmaceuticals Profile

More Earnings Resources from MarketBeat